loading
Lexicon Pharmaceuticals Inc stock is traded at $0.3418, with a volume of 47.60M. It is down -51.17% in the last 24 hours and down -53.04% over the past month. Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.
See More
Previous Close:
$0.6995
Open:
$0.3746
24h Volume:
47.60M
Relative Volume:
8.79
Market Cap:
$147.85M
Revenue:
$1.21M
Net Income/Loss:
$-177.12M
P/E Ratio:
-0.4273
EPS:
-0.8
Net Cash Flow:
$-162.37M
1W Performance:
-51.35%
1M Performance:
-53.04%
6M Performance:
-78.78%
1Y Performance:
-86.23%
1-Day Range:
Value
$0.34
$0.4498
1-Week Range:
Value
$0.35
$0.746
52-Week Range:
Value
$0.35
$2.8291

Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile

Name
Name
Lexicon Pharmaceuticals Inc
Name
Phone
(281) 863-3000
Name
Address
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
Name
Employee
285
Name
Twitter
@LexPharma
Name
Next Earnings Date
2024-11-06
Name
Latest SEC Filings
Name
LXRX's Discussions on Twitter

Compare LXRX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
LXRX
Lexicon Pharmaceuticals Inc
0.3423 147.85M 1.21M -177.12M -162.37M -0.80
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
490.02 124.35B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
688.15 75.07B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
634.08 37.96B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
242.19 31.79B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
BNTX
Biontech Se Adr
112.76 27.34B 3.30B -501.07M 1.03B -2.1146

Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades

Date Action Analyst Rating Change
Jun-17-24 Initiated H.C. Wainwright Buy
Apr-30-24 Initiated Leerink Partners Outperform
Mar-07-23 Initiated Jefferies Hold
Aug-12-22 Initiated Piper Sandler Overweight
Jan-29-21 Upgrade JP Morgan Underweight → Neutral
Jan-29-21 Downgrade Wedbush Outperform → Neutral
Dec-08-20 Upgrade Citigroup Neutral → Buy
Nov-18-20 Upgrade Gabelli & Co Hold → Buy
Dec-11-19 Downgrade Gabelli & Co Buy → Hold
Nov-08-19 Downgrade Citigroup Buy → Neutral
Sep-11-19 Upgrade Gabelli & Co Hold → Buy
Jul-29-19 Downgrade Stifel Buy → Hold
Mar-25-19 Upgrade Gabelli & Co Sell → Hold
Jul-31-18 Reiterated Stifel Buy
Feb-23-18 Downgrade Needham Buy → Hold
Feb-14-18 Downgrade JP Morgan Neutral → Underweight
Mar-01-17 Reiterated H.C. Wainwright Buy
Mar-01-17 Reiterated Wedbush Outperform
Oct-07-16 Initiated H.C. Wainwright Buy
Aug-05-16 Reiterated Wedbush Outperform
Aug-02-16 Initiated Citigroup Buy
Mar-02-16 Reiterated Wedbush Outperform
Nov-09-15 Reiterated Wedbush Outperform
Sep-28-15 Upgrade Gabelli & Co Sell → Hold
Sep-18-15 Downgrade Gabelli & Co Hold → Sell
Aug-10-15 Downgrade JP Morgan Overweight → Neutral
View All

Lexicon Pharmaceuticals Inc Stock (LXRX) Latest News

pulisher
09:34 AM

Lexicon Pharmaceuticals (LXRX) Stock Is Down: What's Going On? - Benzinga

09:34 AM
pulisher
09:00 AM

Lexicon Says Pilavapadin Showed 'Meaningful' Pain Reduction But Results Miss Primary Endpoint - Marketscreener.com

09:00 AM
pulisher
08:24 AM

Lexicon Pharmaceuticals stock tumbles after clinical study results - Investing.com India

08:24 AM
pulisher
07:30 AM

Lexicon advances pilavapadin into Phase 3 for diabetic pain - Investing.com India

07:30 AM
pulisher
07:26 AM

Lexicon Pharmaceuticals Announces Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain - The Manila Times

07:26 AM
pulisher
07:02 AM

Lexicon Pharma (LXRX) Announces Topline Results from Phase 2b PROGRESS Study - StreetInsider.com

07:02 AM
pulisher
07:00 AM

Can Lexicon's Non-Opioid Pain Drug Break 20-Year Innovation Drought? Phase 2b Results Reveal Path Forward - StockTitan

07:00 AM
pulisher
06:28 AM

Lexicon Pharma To Announce Topline Results From Phase 2b PROGRESS Study Today - Nasdaq

06:28 AM
pulisher
Mar 02, 2025

Lexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain - The Manila Times

Mar 02, 2025
pulisher
Mar 02, 2025

Lexicon Pharmaceuticals to Host Conference Call on Phase 2b Results for Pilavapadin in Diabetic Peripheral Neuropathic Pain - Nasdaq

Mar 02, 2025
pulisher
Mar 02, 2025

Can Lexicon's Non-Opioid Drug Transform Diabetic Pain Treatment? Phase 2b Results Coming - StockTitan

Mar 02, 2025
pulisher
Feb 20, 2025

Lexicon Pharmaceuticals, Inc. Announces Resignation of Praveen Tyle as Executive Vice President, Research and Development, Effective as of April 26, 2021 - Marketscreener.com

Feb 20, 2025
pulisher
Feb 18, 2025

Lexicon to cut 50% of workforce to focus on sotagliflozin - MSN

Feb 18, 2025
pulisher
Feb 18, 2025

Published Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE) - Yahoo Finance

Feb 18, 2025
pulisher
Feb 18, 2025

Revolutionary Diabetes Drug Cuts Heart Attack Risk by 32%Landmark Study Results - StockTitan

Feb 18, 2025
pulisher
Feb 13, 2025

Lexicon Has A Lot Riding On LX9211 Phase IIb Readout In Pain - News & Insights

Feb 13, 2025
pulisher
Feb 10, 2025

Merck: 4 No-Brainer Reasons to Buy This Dip - The Globe and Mail

Feb 10, 2025
pulisher
Feb 05, 2025

Peripheral Neuropathic Pain Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Grünenthal and Averitas Pharma, Scilex Pharma, Apurano Pharma, Lexicon Pharma, Helixmith - Barchart

Feb 05, 2025
pulisher
Feb 05, 2025

Peripheral Neuropathic Pain Market to Show Remarkable Growth - openPR

Feb 05, 2025
pulisher
Feb 03, 2025

George Medicines appoints Amy Carroll as Senior Vice President of Medical Affairs - GlobeNewswire Inc.

Feb 03, 2025
pulisher
Feb 02, 2025

Lexicon Pharmaceuticals (NASDAQ:LXRX) Earns "Hold" Rating from Needham & Company LLC - MarketBeat

Feb 02, 2025
pulisher
Feb 02, 2025

Lexicon Pharmaceuticals (NASDAQ:LXRX) Given "Buy" Rating at HC Wainwright - MarketBeat

Feb 02, 2025
pulisher
Feb 02, 2025

HC Wainwright Reiterates "Buy" Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX) - MarketBeat

Feb 02, 2025
pulisher
Jan 31, 2025

More Heart, Less Skin: US FDA’s 2025 Novel Approvals Should Reflect Pipeline Shifts - Citeline News & Insights

Jan 31, 2025
pulisher
Jan 29, 2025

Lexicon Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) - Benzinga

Jan 29, 2025
pulisher
Jan 28, 2025

Lexicon (LXRX) Up as FDA Maintains Action Date for Zynquista - MSN

Jan 28, 2025
pulisher
Jan 28, 2025

9 Health Care Stocks With Whale Alerts In Today's Session - Benzinga

Jan 28, 2025
pulisher
Jan 21, 2025

Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain - The Manila Times

Jan 21, 2025
pulisher
Jan 21, 2025

Lexicon Pharma to Host Expert Panel on Groundbreaking Non-Opioid Pain Treatment LX9211 - StockTitan

Jan 21, 2025
pulisher
Jan 17, 2025

7MM Type 1 Diabetes Market Drug Forecast and Market Analysis 2023-2024 & 2033: Value to Reach $9.91 Billion - GlobeNewswire Inc.

Jan 17, 2025
pulisher
Jan 08, 2025

Lexicon Pharmaceuticals faces potential Nasdaq delisting - Investing.com India

Jan 08, 2025
pulisher
Jan 07, 2025

Lexicon Pharmaceuticals faces potential Nasdaq delisting By Investing.com - Investing.com Nigeria

Jan 07, 2025
pulisher
Jan 07, 2025

Strong week for Lexicon Pharmaceuticals (NASDAQ:LXRX) shareholders doesn't alleviate pain of five-year loss - Simply Wall St

Jan 07, 2025
pulisher
Jan 06, 2025

Here’s Why Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Is Among the Best Diabetes Stocks to Buy Under $10 - Insider Monkey

Jan 06, 2025
pulisher
Jan 03, 2025

Lexicon Pharmaceuticals, Inc. Appoints Scott M. Coiante as Senior Vice President - Marketscreener.com

Jan 03, 2025
pulisher
Jan 03, 2025

Lexicon Pharmaceuticals, Inc. Announces CFO Changes - Marketscreener.com

Jan 03, 2025
pulisher
Jan 02, 2025

Lexicon Pharmaceuticals, Inc. Appoints Scott Coiante as Senior Vice President - Marketscreener.com

Jan 02, 2025
pulisher
Jan 02, 2025

Lexicon Appoints Scott Coiante as Chief Financial Officer - The Manila Times

Jan 02, 2025
pulisher
Jan 02, 2025

Lexicon Pharmaceuticals Names Scott Coiante Finance Chief - MarketWatch

Jan 02, 2025
pulisher
Jan 02, 2025

Lexicon Pharma (LXRX) Appoints Scott Coiante as CFO - StreetInsider.com

Jan 02, 2025
pulisher
Jan 02, 2025

Lexicon Pharmaceuticals Names Veteran Pharma Executive Scott Coiante as New CFO - StockTitan

Jan 02, 2025
pulisher
Dec 31, 2024

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Lexicon Pharmaceuticals, Inc. (LXRX), ProShares Short VIX Short-Term Futures ETF (SVXY) & Alta Mesa Resources, Inc. f/k/a Silver Run Acquisition Cor - AccessWire

Dec 31, 2024
pulisher
Dec 31, 2024

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Shares Acquired by State Street Corp - Defense World

Dec 31, 2024
pulisher
Dec 30, 2024

Private equity firms account for 47% of Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) ownership, while institutions account for 33% - Yahoo Finance

Dec 30, 2024
pulisher
Dec 30, 2024

Sotagliflozin Not Approved as Type 1 Diabetes Add-On - Medscape

Dec 30, 2024
pulisher
Dec 24, 2024

Lexicon Pharmaceuticals (NASDAQ:LXRX) Receives “Hold” Rating from Needham & Company LLC - Defense World

Dec 24, 2024
pulisher
Dec 23, 2024

Lexicon Zynquista vista narrows with diabetes CRL; gain due in pain? - BioWorld Online

Dec 23, 2024
pulisher
Dec 23, 2024

Needham & Company LLC Reiterates Hold Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX) - MarketBeat

Dec 23, 2024
pulisher
Dec 23, 2024

Analyst Expectations For Lexicon Pharmaceuticals's Future - Benzinga

Dec 23, 2024
pulisher
Dec 22, 2024

XTX Topco Ltd Makes New Investment in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - Defense World

Dec 22, 2024
pulisher
Dec 21, 2024

Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin) - The Manila Times

Dec 21, 2024

Lexicon Pharmaceuticals Inc Stock (LXRX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Lexicon Pharmaceuticals Inc Stock (LXRX) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Swain Judith L
Director
Apr 28 '24
Option Exercise
0.00
8,032
0
48,364
SOBECKI CHRISTOPHER J
Director
Apr 28 '24
Option Exercise
0.00
8,032
0
167,055
LEFKOWITZ ROBERT J MD
Director
Apr 28 '24
Option Exercise
0.00
8,032
0
48,364
DEBBANE RAYMOND
Director
Apr 28 '24
Option Exercise
0.00
8,032
0
1,348,879
BARKER SAM L
Director
Apr 28 '24
Option Exercise
0.00
8,032
0
87,649
Amouyal Philippe
Director
Apr 28 '24
Option Exercise
0.00
8,032
0
248,364
$78.28
price down icon 4.34%
$23.06
price up icon 1.68%
$33.94
price up icon 1.01%
$19.96
price down icon 4.11%
biotechnology ONC
$245.22
price down icon 9.75%
$112.79
price down icon 0.24%
Cap:     |  Volume (24h):